top of page
News, Events and Updates
Search
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)
Jul 5, 2020
First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine)
Jun 30, 2020
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 U.S Phase 2 Trial
Jun 15, 2020
Anavex Life Sciences Receives Approval from Health Canada & UK MHRA Expanding Phase 2b/3 ANAVEX®2-73
Jun 3, 2020
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)
May 21, 2020
Anavex Life Sciences Reports Fiscal 2020 2nd Quarter Financial Results And Provides Business Updates
May 7, 2020
Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results
May 4, 2020
Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 in Alzheimer's Disease
Apr 22, 2020
Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19
Mar 30, 2020
Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders
Mar 22, 2020
Anavex Life Sciences Announces Foundational Data for ANAVEX®2-73 in Multiple Sclerosis (MS)
Feb 24, 2020
16
17
18
19
20
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
